Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?

Pedro Luiz Serrano Uson Junior; Bolni Marius Nagalo; Daniel H. Ahn; Tanios Bekaii-Saab; Mitesh J. Borad

doi:10.1055/s-0040-1722646

Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?

Pedro Luiz Serrano Uson Junior, Bolni Marius Nagalo, Daniel H. Ahn, Tanios Bekaii-Saab, Mitesh J. Borad

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.

Original language	English (US)
Pages (from-to)	136-141
Number of pages	6
Journal	Seminars in liver disease
Volume	41
Issue number	2
DOIs	https://doi.org/10.1055/s-0040-1722646
State	Published - May 1 2021

Keywords

anti-CTLA-4
anti-PD-1
checkpoint inhibitors
hepatocellular carcinoma
liver

ASJC Scopus subject areas

Hepatology

Access to Document

10.1055/s-0040-1722646

Cite this

@article{731ae260f561447cb6fbce07d50d0c21,

title = "Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?",

abstract = "The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.",

keywords = "anti-CTLA-4, anti-PD-1, checkpoint inhibitors, hepatocellular carcinoma, liver",

author = "{Uson Junior}, {Pedro Luiz Serrano} and Nagalo, {Bolni Marius} and Ahn, {Daniel H.} and Tanios Bekaii-Saab and Borad, {Mitesh J.}",

year = "2021",

month = may,

day = "1",

doi = "10.1055/s-0040-1722646",

language = "English (US)",

volume = "41",

pages = "136--141",

journal = "Seminars in liver disease",

issn = "0272-8087",

publisher = "Thieme Medical Publishers",

number = "2",

}

TY - JOUR

T1 - Combination Immunotherapy for Hepatocellular Carcinoma

T2 - Where Are We Currently?

AU - Uson Junior, Pedro Luiz Serrano

AU - Nagalo, Bolni Marius

AU - Ahn, Daniel H.

AU - Bekaii-Saab, Tanios

AU - Borad, Mitesh J.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.

AB - The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.

KW - anti-CTLA-4

KW - anti-PD-1

KW - checkpoint inhibitors

KW - hepatocellular carcinoma

KW - liver

UR - http://www.scopus.com/inward/record.url?scp=85105876500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105876500&partnerID=8YFLogxK

U2 - 10.1055/s-0040-1722646

DO - 10.1055/s-0040-1722646

M3 - Article

C2 - 33957697

AN - SCOPUS:85105876500

SN - 0272-8087

VL - 41

SP - 136

EP - 141

JO - Seminars in liver disease

JF - Seminars in liver disease

IS - 2

ER -

Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this